Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011-A00764-37 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The MAPT PLUS study is a two-year extension of follow-up of the patients included in the MAPT preventive study, after completion of the interventions. Subjects in the four groups of the MAPT study will be prospectively followed. MAPT is a multicentre, randomised, placebo-controlled study, using a 4-group design with 3 treatment groups (omega 3 alone, multi-domain intervention alone, omega 3 plus multi-domain intervention, n=420 each) and a placebo group (n=420). The MAPT PLUS study will be an extension of the MAPT study and includes an annual follow-up for two years.
The MAPT PLUS study is a follow-up of subjects initially included in an interventional study. The follow-up that we propose in this request for funding does not involve any intervention, but aims to assess the long-term effect of the interventions previously carried out during the three years of the MAPT study.
* Description of the interventions to which subjects are exposed during the first 3 years of follow-up (MAPT study) :
In the MAPT study, subjects are randomized into 4 groups:
The collective sessions take place in groups of 6 to 8 subjects. In the first month, two sessions a week are scheduled, and in the second month, one session a week. The first two months correspond to the intensive programme. Each session comprises 1 hour of cognitive training, 45 minutes of information on physical activity and 15 minutes of dietary advice. From the third month, sessions are held monthly and aim to consolidate the key messages and to stimulate adherence to the programme. The sessions are shorter (1 hour review of one of the domains of the intensive programme). " Booster " sessions (2 hours) are delivered at 12 and 24 months after the first sessions of the intensive programme. Twenty-minute individual interviews also take place every 6 months with the leader of the training sessions (6 interviews in the course of 3 years).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Gröber and Buschke test |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gröber and Buschke test | Behavioral | spontaneous delayed recall score after a 5 years follow-up |
|
| Measure | Description | Time Frame |
|---|---|---|
| Gröber and Buschke test (spontaneous delayed recall score) | Assessment of cognitive and functional performances according to the spontaneous delayed recall score(Gröber and Buschke test) | 2 years |
| Cognitive and functional performance (Gröber and Buschke test-spontaneous delayed recall score) | Assessment of cognitive and functional performances by using the Gröber and Buschke test (spontaneous delayed recall score)at 5 years after the participation to the MAPT study. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| MRI test | Evaluation of the long-term impact of MAPT study interventions on changes in markers of cerebral atrophy (overall brain volume of specific brain structures such as the hippocampus) | 2 years |
| Cost-effectiveness Evaluation |
Not provided
Inclusion Criteria:
Subjects who meet the following criteria will be included in the MAPT PLUS study :
Exclusion Criteria:
Subjects who fulfill at least one of the following criteria will not be included in the MAPT PLUS study :
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bruno Vellas, MD | University Hospital, Toulouse | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bordeaux | Bordeaux | France | ||||
| CH Castres-Mazamet |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37872582 | Derived | Delrieu J, Vellas B, Guyonnet S, Cantet C, Ovod V, Li Y, Bollinger J, Bateman R, Andrieu S; MAPT/DSA group. Cognitive impact of multidomain intervention and omega 3 according to blood Abeta42/40 ratio: a subgroup analysis from the randomized MAPT trial. Alzheimers Res Ther. 2023 Oct 23;15(1):183. doi: 10.1186/s13195-023-01325-3. | |
| 33666880 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D000073496 | Frailty |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Evaluation of the long-term impact of the MAPT interventions in terms of cost-effectiveness ratio by using a medico-economic data collection
| 2 years |
| Castres |
| France |
| CHRU Dijon | Dijon | France |
| CHIVA | Foix | France |
| LAVAUR | Lavaur | France |
| CHU Limoges | Limoges | France |
| Lyon-Sud Hospital | Lyon | France |
| Chg Montauban | Montauban | 82000 | France |
| CHU Montpellier | Montpellier | France |
| Nice | Nice | France |
| Tarbes | Tarbes | France |
| UH Toulouse - La Grave | Toulouse | 31059 | France |
| CH Princesse GrĂ¢ce | Monaco | Monaco |
| Takano E, Maltais M, Kondo I, Rolland Y; MAPT/DSA group. Bidirectional relationship between depressive symptoms and physical performance in community-dwelling older people with subjective memory complaints. Eur Geriatr Med. 2021 Oct;12(5):973-980. doi: 10.1007/s41999-021-00473-9. Epub 2021 Mar 5. |
| 33076983 | Derived | Delrieu J, Voisin T, Saint-Aubert L, Carrie I, Cantet C, Vellas B, Payoux P, Andrieu S. The impact of a multi-domain intervention on cerebral glucose metabolism: analysis from the randomized ancillary FDG PET MAPT trial. Alzheimers Res Ther. 2020 Oct 19;12(1):134. doi: 10.1186/s13195-020-00683-6. |
| 31558366 | Derived | Delrieu J, Payoux P, Carrie I, Cantet C, Weiner M, Vellas B, Andrieu S. Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. Alzheimers Dement. 2019 Nov;15(11):1392-1401. doi: 10.1016/j.jalz.2019.07.008. Epub 2019 Sep 23. |
| 30498824 | Derived | Pothier K, de Souto Barreto P, Maltais M, Rolland Y, Vellas B. Shifting from Declines to Improvements: Associations between a Meaningful Walking Speed Change and Cognitive Evolution over Three Years in Older Adults. J Nutr Health Aging. 2018;22(10):1183-1188. doi: 10.1007/s12603-018-1059-8. |
| 30207586 | Derived | Lilamand M, Cesari M, Cantet C, Payoux P, Andrieu S, Vellas B; the MAPT/DSA study group. Relationship Between Brain Amyloid Deposition and Instrumental Activities of Daily Living in Older Adults: A Longitudinal Study from the Multidomain Alzheimer Prevention Trial. J Am Geriatr Soc. 2018 Oct;66(10):1940-1947. doi: 10.1111/jgs.15497. Epub 2018 Sep 12. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |